Department of health in UK to consult on value-based pricing this week
This article was originally published in Scrip
Executive Summary
The department of health in the UK will this week launch for consultation its plans to introduce value-based pricing for pharmaceuticals, it has told Scrip. The consultation will touch on the government's plans for NICE, the health technology appraisal institute, which will see the institute cede to GPs (primary care physicians) its authority to definitively recommend whether or not to make certain drugs available on the NHS.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.